A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Bardoxolone Methyl on Residual Renal Function (RRF) in Patients with End-Stage Renal Disease (ESRD) and Type 2 Diabetes Mellitus (T2DM) on Peritoneal Dialysis (PD)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bardoxolone methyl (Primary)
Indications Renal failure; Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Reata Pharmaceuticals

Most Recent Events

01 Oct 2012 Status changed from recruiting to withdrawn prior to recruitment, as reported in a Reata Pharmaceuticals media release.
21 Jul 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-001563-78).
03 Jul 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight